Literature DB >> 28798221

eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study.

Nisha Bansal1, Leila R Zelnick2, Alvaro Alonso3, Emelia J Benjamin4, Ian H de Boer2,5, Rajat Deo6, Ronit Katz2, Bryan Kestenbaum2, Jehu Mathew7, Cassianne Robinson-Cohen2, Mark J Sarnak8, Michael G Shlipak9, Nona Sotoodehnia10,11, Bessie Young2,5, Susan R Heckbert11,12.   

Abstract

BACKGROUND AND OBJECTIVES: The incidence of atrial fibrillation is high in ESRD, but limited data are available on the incidence of atrial fibrillation across a broad range of kidney function. Thus, we examined the association of eGFR and urine albumin-to-creatinine ratio with risk of incident atrial fibrillation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We meta-analyzed three prospective cohorts: the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Cox regression models were performed examining the association of eGFR and urine albumin-to-creatinine ratio with incident atrial fibrillation adjusting for demographics and comorbidity. In additional analyses, we adjusted for measures of subclinical cardiovascular disease (by electrocardiogram and cardiac imaging) and interim heart failure and myocardial infarction events.
RESULTS: In the meta-analyzed study population of 16,769 participants without prevalent atrial fibrillation, across categories of decreasing eGFR (eGFR>90 [reference], 60-89, 45-59, 30-44, and <30 ml/min per 1.73 m2), there was a stepwise increase in the adjusted risk of incident atrial fibrillation: hazard ratios (95% confidence intervals) were 1.00, 1.09 (0.97 to 1.24), 1.17 (1.00 to 1.38), 1.59 (1.28 to 1.98), and 2.03 (1.40 to 2.96), respectively. There was a stepwise increase in the adjusted risk of incident atrial fibrillation across categories of increasing urine albumin-to-creatinine ratio (urine albumin-to-creatinine ratio <15 [reference], 15-29, 30-299, and ≥300 mg/g): hazard ratios (95% confidence intervals) were 1.00, 1.04 (0.83 to 1.30), 1.47 (1.20 to 1.79), and 1.76 (1.18 to 2.62), respectively. The associations were consistent after adjustment for subclinical cardiovascular disease measures and interim heart failure and myocardial infarction events.
CONCLUSIONS: In this meta-analysis of three cohorts, reduced eGFR and elevated urine albumin-to-creatinine ratio were significantly associated with greater risk of incident atrial fibrillation, highlighting the need for further studies to understand mechanisms linking kidney disease with atrial fibrillation.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  albuminuria; cardiovascular disease; chronic kidney disease

Mesh:

Substances:

Year:  2017        PMID: 28798221      PMCID: PMC5586568          DOI: 10.2215/CJN.01860217

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  72 in total

1.  Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study.

Authors:  Myra A Carpenter; Richard Crow; Michael Steffes; William Rock; Jeffrey Heilbraun; Gregory Evans; Thomas Skelton; Robert Jensen; Daniel Sarpong
Journal:  Am J Med Sci       Date:  2004-09       Impact factor: 2.378

2.  Clinically silent myocardial infarctions in the CKD community.

Authors:  Nisha Bansal
Journal:  Nephrol Dial Transplant       Date:  2012-06-18       Impact factor: 5.992

3.  Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description.

Authors:  Sonja R Fuqua; Sharon B Wyatt; Michael E Andrew; Daniel F Sarpong; Frances R Henderson; Margie F Cunningham; Herman A Taylor
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

4.  European ancestry as a risk factor for atrial fibrillation in African Americans.

Authors:  Gregory M Marcus; Alvaro Alonso; Carmen A Peralta; Guillaume Lettre; Eric Vittinghoff; Steven A Lubitz; Ervin R Fox; Yamini S Levitzky; Reena Mehra; Kathleen F Kerr; Rajat Deo; Nona Sotoodehnia; Meggie Akylbekova; Patrick T Ellinor; Dina N Paltoo; Elsayed Z Soliman; Emelia J Benjamin; Susan R Heckbert
Journal:  Circulation       Date:  2010-11-16       Impact factor: 29.690

5.  Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients.

Authors:  Takeshi Horio; Yoshio Iwashima; Kei Kamide; Takeshi Tokudome; Fumiki Yoshihara; Satoko Nakamura; Yuhei Kawano
Journal:  J Hypertens       Date:  2010-08       Impact factor: 4.844

6.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

7.  Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity.

Authors:  Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

8.  Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System.

Authors:  E J Erlandsen; E Randers; J H Kristensen
Journal:  Scand J Clin Lab Invest       Date:  1999-02       Impact factor: 1.713

9.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom
Journal:  Am Heart J       Date:  2009-07       Impact factor: 4.749

10.  Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium.

Authors:  Alvaro Alonso; Bouwe P Krijthe; Thor Aspelund; Katherine A Stepas; Michael J Pencina; Carlee B Moser; Moritz F Sinner; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Sunil K Agarwal; David D McManus; Patrick T Ellinor; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Elsayed Z Soliman; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Emelia J Benjamin
Journal:  J Am Heart Assoc       Date:  2013-03-18       Impact factor: 5.501

View more
  20 in total

Review 1.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data.

Authors:  Luca Di Lullo; Giovanni Tripepi; Claudio Ronco; Antonio De Pascalis; Vincenzo Barbera; Antonio Granata; Domenico Russo; Biagio Raffaele Di Iorio; Ernesto Paoletti; Maura Ravera; Maria Fusaro; Antonio Bellasi
Journal:  J Nephrol       Date:  2018-06-07       Impact factor: 3.902

3.  Atrial fibrillation and kidney disease: insights on a close relationship.

Authors:  Giorgio Trivioli
Journal:  Intern Emerg Med       Date:  2019-07-17       Impact factor: 3.397

4.  Rates of Cardiac Rhythm Abnormalities in Patients with CKD and Diabetes.

Authors:  Nazem Akoum; Leila R Zelnick; Ian H de Boer; Irl B Hirsch; Dace Trence; Connor Henry; Nicole Robinson; Nisha Bansal
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-19       Impact factor: 8.237

Review 5.  Atrial fibrillation and chronic kidney disease conundrum: an update.

Authors:  Laura Tapoi; Carina Ureche; Radu Sascau; Silvia Badarau; Adrian Covic
Journal:  J Nephrol       Date:  2019-07-18       Impact factor: 3.902

6.  Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease: The Stockholm CREAtinine Measurements (SCREAM) Project.

Authors:  Juan Jesus Carrero; Marco Trevisan; Manish M Sood; Peter Bárány; Hong Xu; Marie Evans; Leif Friberg; Karolina Szummer
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-20       Impact factor: 8.237

7.  Atrial fibrillation in an African-American cohort: The Jackson Heart Study.

Authors:  Thomas R Austin; Kerri L Wiggins; Chad Blackshear; Yi Yang; Emelia J Benjamin; Lesley H Curtis; Nona Sotoodehnia; Adolfo Correa; Susan R Heckbert
Journal:  Clin Cardiol       Date:  2018-08-17       Impact factor: 2.882

8.  Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis.

Authors:  Chen Chen; Yalin Cao; Ying Zheng; Yugang Dong; Jianyong Ma; Wengen Zhu; Chen Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-02-04       Impact factor: 3.727

9.  The prevalence of atrial fibrillation on 48-hour ambulatory electrocardiography in African Americans compared to Whites: The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Laura R Loehr; Elsayed Z Soliman; Anna K Poon; David Couper; Lin Yee Chen; Thomas H Mosley; Lynne E Wagenknecht; Eric A Whitsel; Alvaro Alonso; Lisa Wruck; Gerardo Heiss
Journal:  Am Heart J       Date:  2019-07-03       Impact factor: 4.749

10.  Association of proteinuria with incident atrial fibrillation in the general Japanese population.

Authors:  Yoshihiro Tanaka; Hayato Tada; Satoshi Hara; Kenshi Hayashi; Ravi B Patel; Tetsuo Nishikawa; Atsushi Hashiba; Masayuki Takamura; Philip Greenland; Masa-Aki Kawashiri
Journal:  J Cardiol       Date:  2020-08-23       Impact factor: 3.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.